Background: Awake craniotomy with intraoperative speech or motor testing is relatively contraindicated in cases requiring prolonged operative times and in patients with severe medical comorbidities including anxiety, anticipated difficult airway, obesity, large tumors, and intracranial hypertension. The anesthetic management of neurosurgical patients who possess these contraindications but would be optimally treated by an awake procedure remains unclear.
A wake craniotomy with motor or speech mapping has been shown to improve both the efficacy and safety of primary and metastatic tumor resection. [1] [2] [3] [4] [5] [6] [7] Numerous different anesthetic approaches have been designed to facilitate the surgical goals of awake craniotomy, including the use of diverse anesthetic agents and airway management techniques. [8] [9] [10] [11] [12] [13] [14] Achievement of an appropriate level of sedation and analgesia, providing both adequate respiratory and hemodynamic control and reliable conditions for awake mapping, remains a significant challenge for the anesthesiologist and a barrier to the application of awake surgery.
Considerations of patient safety have led to concerns about the performance of awake craniotomy in the presence of relative contraindications such as uncooperative patients, anxiety, poor neurological status, anticipated difficult airway, severe chronic obstructive pulmonary disease (COPD), obstructive sleep apnea, obesity, gastroesophageal reflux, and large tumor with midline shift. 1, 2, [9] [10] [11] [12] 15 The presence of these comorbid conditions would be considered popular reasons to consider the use of regional anesthesia and sedation in other procedures (eg, hip or knee arthroplasty). However, the main difference in the awake craniotomy procedure would be severity of the adverse effects of oversedation and airway obstruction in clinical situations, wherein the airway is not readily accessible (as it would be for regional anesthesia for hip and knee surgery) and the consequence of having to manage an emergent airway obstruction with an exposed and vulnerable brain. Furthermore, episodes of respiratory depression and/or airway obstruction can lead to hypercarbia that has been long known as a potent stimulator of cerebral blood flow with risks for intraoperative brain bulging and increased surgical difficulty.
Balancing these relative contraindications with the potential patient benefit of awake craniotomy to patient outcome lead us to revisit the use of awake craniotomy in these patients. Although a traditional approach would require intermittent management of the airway with a laryngeal mask or oral tracheal tube at critical points during the surgery, the ideal surgical conditions provided by our technique have allowed us to expand upon this approach and perform awake craniotomy for extended times safely, providing patient comfort and ideal surgical conditions without the need for any airway manipulation or the use of airway devices.
Here we describe an anesthetic technique based on scalp nerve blocks 16, 17 and dexmedetomidine 18 without any airway manipulation applied to 10 patients at a high risk of failure and complications for awake craniotomy and a case series of 4 patients who otherwise might not be deemed suitable candidates for this procedure from an anesthesia perspective.
METHODS

Subjects
The anesthetic team assessed 10 high-risk patients (Table 1) who underwent awake craniotomy with intraoperative speech and/or motor mapping for brain tumor resection between March 5 and December 11, 2012. All treatable comorbid conditions were optimized preoperatively. Medical consultation was obtained when needed to assist with patient optimization. We did not have set criteria to assess the severity of the anxiety disorders and the assessment was based on the patient's history, use of medication, and clinical judgment of the neurosurgeon and the attending anesthesiologist. Radiologic brain imaging (computed tomography/magnetic resonance imaging) was used to assess the presence of intracranial mass effect with midline shift.
Local Ethics Committee approval was obtained for chart review. Patients' demographic data, body mass index, and comorbidities have been listed in Table 2 .
Anesthetic Technique
Patients arrived in the operating room with a standard peripheral IV line in situ (18 G) . No premedication was used. Standard noninvasive monitors (ECG, pulse oximeter, arterial blood pressure cuff, and thoracic impedance plethysmography) were placed. Oxygen was provided through a facial mask at 3 L/min with end-tidal carbon dioxide monitoring. Ondansetron 4 mg IV was administered. Considering the high-risk population, duration of surgery, and the potential hemodynamic effect of dexmedetomidine, a radial artery catheter was inserted.
For all the 10 patients, dexmedetomidine was administered as the following (Fig. 1) .
(1) A loading dose of 0.5 to 1 mg/kg in small boluses was administered over 10 to 15 minutes (target Richmond Agitation Sedation Score [RASS] of 0/À 1- Table 3 19 ). (2) During or following the completion of the loading dose, an infusion of 0.3 to 0.4 mg/kg/h was started. (3) During the procedure, a mean infusion rate was maintained at 0.2 to 0.7 mg/kg/h (RASS: À 1/ À 2) until 10 to 15 minutes before the intended awakening for neurological testing. (4) The infusion was resumed following the completion of the intraoperative testing and maintained in the stated range until closure of the skin, after which the infusion was discontinued. The anesthetic base was supplemented with a low dose of opioid or midazolam as needed. 20, 21 The synergistic interaction between benzodiazepine and dexmedetomidine is useful in patients with a history of anxiety disorders, who can easily get stressed, despite successful scalp nerve blocks. Moreover, considering some painful intraoperative moments (head pin fixation, manipulation of the dura, closure after tumor resection), length of surgery, and according to the individual needs of each patient, a careful titration of low-dose opioid throughout the procedure can lead to a successful balance between analgesia and sedation without affecting patient cooperation for neurological testing and maintaining a normal respiratory drive.
Operative Protocol
Following their arrival in the operating room, patients were administered dexmedetomidine as detailed above. An 8-point scalp nerve block using 0.375% bupivacaine without epinephrine (20 to 25 mL) was performed. 16 At each injection site, 2 to 3 mL of local infiltrate was used. The patients were then secured in a Mayfield head holder. Pin sites were infiltrated with lidocaine 2% (5 to 10 mL) before clamp placement. The incision line was infiltrated with 6 to 10 mL of 0.5% bupivacaine without epinephrine. Additional infiltration of the muscle and topical anesthesia of the dura were used when needed (lidocaine 2%).
The dexmedetomidine infusion was discontinued following the opening of the dura. Cortical and subcortical mapping for speech and motor function were performed using a bipolar stimulator (Integra). Patients were monitored for both positive and negative findings. Cold saline was applied to the brain surface in cases in which seizures were induced. The dexmedetomidine infusion was resumed following the completion of intraoperative testing and continued through tumor resection and craniotomy closure.
RESULTS
Ten patients, 6 men and 4 women, with a mean age of 55.7 years (range, 29 to 80 y), underwent awake craniotomy with successful intraoperative mapping of speech or motor function (Tables 2 and 4 ). The median duration of surgery was 3.5 hours (range, 3 to 9 h) and total intraoperative drugs dose consumption has been indicated in Table 5 . No anesthetic or neurosurgical complications were encountered. With the patient fully cooperative, an awake mapping was performed (RASS: 0) 10 to 15 minutes from the discontinuation of the dexmedetomidine infusion. In no case was it necessary to convert to a general anesthesia or perform airway manipulations. We detail 4 cases below that highlight our experience.
Case 1
A 29-year-old left-handed man presented for craniotomy for the resection of a large right-sided temporoinsular tumor (7.8Â 4.3Â 5.4 cm in size), resulting in the enfacement of the right frontal horn, 8 mm midline shift with uncal herniation, discovered during work-up for partial seizure. His seizures were well controlled on carbamazepine. Physical, neurological, and airway examinations were normal. Given the size and location of the tumor, the surgeon proposed the use of cortical and subcortical mapping for speech and motor function. The duration of the surgery was expected to be 5 to 7 hours, which required multiple intraoperative neurological testing.
Sedation was induced to keep the patient comfortable (RASS: 0/ À 1) with boluses of 8 mg of dexmedetomidine administered over 10 minutes for a total dose of 40 mg (approximately 0.5 mg/kg). An infusion of dexmedetomidine (0.3 mg/kg/h) was started (Fig. 2) .
In addition, boluses of 1 mg of midazolam (total 4 mg) were administered at the beginning of the procedure because of the patient's anxiety regarding the insertion of the Foley catheter. This enhanced the effect of dexmedetomidine extremely, keeping the patient arousable but comfortably sedated.
A low infusion rate of remifentanil at 0.02 mg/kg/ min was also started. The decision to use a short-acting analgesic such as remifentanil was made to prevent hemodynamic responses to painful stimuli during the initial stages of the procedure (pin fixation, dura manipulation) and ensure a continuous synergistic interaction with dexmedetomidine throughout the prolonged procedure without affecting the respiratory drive.
A further 40mg of dexmedetomidine was administered in boluses of 8 mg over 10 minutes. The scalp nerve blocks were performed and the patient was positioned supine in a Mayfield head holder, with the head turned about 45 degrees to the left. Rolls were placed under the left side of the body to ensure the patient's comfort.
The dexmedetomidine infusion was increased to 0.7 mg/kg/h during the opening of the temporalis muscle and bone drilling, and then maintained between 0.2 and 0.6 mg/ kg/h. Considering the expected duration of surgery (Z5 h), the dexmedetomidine infusion was supplemented with a longer acting analgesic (hydromorphone), titrated in boluses of 0.2 mg (total 1.2 mg). This approach greatly facilitated the patient's comfort throughout the initial stages and during the more painful moments of the procedure, ensuring good airway and hemodynamic control. The patient was breathing spontaneously at a rate of 10 to 14 breaths per minute and was arousable, but comfortably sedated and resting with his eyes closed when not stimulated (RASS: À 1/À 2).
Fifteen minutes before the intended awakening for neurological assessment, the dexmedetomidine and remifentanil infusions were discontinued. The patient was able to cooperate fully with speech and motor testing. Cortical speech and motor mapping required approximately 20 minutes. We then resumed the dexmedetomidine infusion at 0.5 mg/kg/h and remifentanil infusion at 0.01 mg/kg/min.
Surgically, the Sylvian fissure was opened, an anterior temporal lobectomy was performed, and the insular tumor was debulked. The resection required skeletonization of the distal middle cerebral artery branches. At 4 to 6 hours from the beginning of the surgery, the surgeon requested to arouse the patient again for neurological testing and subcortical white matter tract mapping. In both the cases, we stopped the infusions 15 minutes before the neurological testing and the surgeon was able to identify the pathways for face and arm motor function.
Following the conclusion of the final mapping, the infusions were resumed at a lower rate (dexmedetomidine at 0.4 mg/kg/h, remifentanil at 0.005 mg/kg/min) and supplemented with 0.2 mg boluses of hydromorphone for a total dose of 0.8 mg. This was beneficial to prevent and control the episode of breakthrough pain at the end of a prolonged awake craniotomy, given that the operative time was nearly 9 hours. A total of 4 arterial blood gas 
Case 2
A 60-year-old woman with metastatic lung cancer presented with recurrent left-sided weakness secondary to reaccumulation of a large tumor-associated cyst in the right frontal lobe. Her medical comorbidities included anxiety, depression, seizures, COPD, a right perihilar mass narrowing the right main bronchus, known as difficult intubation, previous myocardial infarct postlobectomy, pulmonary hypertension, gastroesophageal reflux, and right axillary lymphadenopathy with right-arm edema. Stereotactic cyst drainage through a burr hole had failed twice in the last month before this presentation.
The presence of multiple comorbidities increased the patient's risks for both general anesthesia and awake craniotomy. The location of the tumor, however, mandated cortical motor mapping to ensure a safe plan for access. On preoperative evaluation, the patient was found to be cogent, very cooperative, and motivated to proceed with the awake craniotomy. In the operating room, we simplified the anesthetic protocol. A total loading dose of 0.6 mg/kg of dexmedetomidine was administered in small boluses over 15 minutes (RASS: À 1) and a dexmedetomidine infusion started at 0.4 mg/kg/h. An additional 1 mg of midazolam was administered before the scalp nerve blocks and pin placement. During the procedure, dexmedetomidine was infused at the range of 0.3 to 0.7 mg/ kg/h to keep the patient comfortable but easily arousable and cooperative (RASS: 0/ À 1). Motor mapping was performed with successful positive and negative identification of the motor cortex. The surgery was completed uneventfully in 3 hours. Spontaneous ventilation was maintained throughout the procedure with a mean (SD) PaCO 2 of 48 mm Hg (3.7 mm Hg) on the intraoperative arterial blood gas.
Case 3
A 79-year-old woman with a history of lung cancer and progressive right-sided weakness and speech disturbance was found to have a left frontal brain lesion with surrounding vasogenic edema, consistent with metastatic disease. The patient's past medical history was positive for prior stroke, hypertension, right upper lobe lung lesion, severe COPD with diffused wheezing and frequent episodes of coughing, and 80 pack-year smoking. Her oxygen saturation on room air was 94%. Before starting the procedure, salbutamol and dexamethasone 8 mg IV were administered. The patient then received a loading dose of dexmedetomidine (0.5 mg/kg) over 10 minutes and fentanyl 50 mg (RASS: À 1/ À 2). A dexmedetomidine infusion was started and maintained at 0.2 to 0.6 mg/kg/h. Scalp nerve blocks were performed as described above. As in case 2, the patient was comfortable but easily aroused and cooperative throughout the procedure. Neurological testing and cortical mapping were carried out for both motor and speech cortex, with identification of the motor cortex by negative stimulation. The procedure was completed in <3 hours without any complications.
Case 4
A 38-year-old left-handed man with a past medical history of severe anxiety disorder and panic attacks was discovered to have a right frontal lesion in the opercular area during work-up for a secondarily generalized tonic-clonic seizure. The preoperative work-up failed to identify the laterality of language function. The patient was administered a total of 4 mg of midazolam to control his extreme anxiety and avoid panic attacks. A loading dose of 0.7 mg/kg of dexmedetomidine was administered before the start of the procedure and during setup, and concurrently an infusion of dexmedetomidine was started and maintained in a range of 0.5 to 1 mg/kg/h. Neurological testing and cortical mapping were carried out for both motor and speech cortex, with identification of the motor cortex immediately posterior to the lesion by negative and positive stimulation. A gross total resection was performed. The procedure was completed in <3 hours without any complications.
DISCUSSION
We describe a successful anesthetic approach without the need for any airway manipulation based on scalp nerve blocks and dexmedetomidine as the primary sedative agent for awake craniotomy for tumor resection in a cohort of patients at a high risk of failure and complications, characterized by traditional contraindications to awake surgery.
Although there is quite a mature literature on awake craniotomy and the use of dexmedetomidine, there is still no consensus about the optimal regimen to use. 10 Furthermore, the literature is lacking with respect to the management of complex patients at a high risk of failure and complications. Only in a recent letter to the editor, Chung et al 22 described their anesthetic management of awake craniotomy in high-risk patients, utilizing dexmedetomidine and laryngeal mask. However, our anesthetic technique differs, as it does not include elective intraoperative airway device insertion, such as supraglottic devices, which carry the risk of inducing coughing, Valsalva maneuver, unwanted brain herniation through the craniotomy site, vomiting, or movement during the procedure. These events could increase the risk for cerebral swelling, bleeding, or potential air embolism. Rather, we have relied on a relatively simple protocol based on the use of local anesthetics (scalp nerve blocks, pin site, and incision line infiltration), dexmedetomidine, and the synergistic interaction with low doses of opioid and midazolam, which have greatly facilitated the conditions of anesthesia and surgical management in a more complex patient population.
Dexmedetomidine has numerous drug properties that make it an attractive candidate for anesthetic management during awake craniotomy. 8, 13, 18, [23] [24] [25] [26] It is a highly selective a-2-adrenergic agonist, with dose-dependent sedative, anxiolytic, and analgesic properties, that does not induce ventilatory suppression. 13, 23, 24, 27 Dosedependent bradycardia and decrease in blood pressure are the most common hemodynamic effects of dexmedetomidine and occur as a result of its agonistic effect on the a-2 adrenoreceptors. 18, 23 It has been advocated as a primary agent for sedation in patients with severe lung diseases (pulmonary fibrosis, asthma, or COPD) because of its limited effects on cardiopulmonary function. 28 At our institution, we safely used a simple technique without airway manipulation based on the use of dexmedetomidine in addition to scalp nerve blocks for 10 complex patients, despite the presence of relative contraindications to awake surgery, including prolonged surgical time and intracranial hypertension, difficult airway, COPD, and severe anxiety. Although anxiety disorders are not considered an absolute exclusion criterion, a recent pilot study on the eligibility criteria and psychological profiles of patient candidates for awake craniotomy showed that the most common warning signs for minor failure of awake craniotomy were fear of pain and patient anxiety. 15 The presence of midline shift, an evidence of increased intracranial pressure, might also be considered a relative contraindication because this can lead to intraoperative brain bulging with poor surgical condition once the dura mater is opened. Furthermore, in our patients, hyperventilation through mechanical ventilation could not be used to compensate increases in intracranial pressure or control brain swelling because no airway devices were used. In all of these cases, we felt that the increased risk for perioperative complications associated with awake surgery was outweighed by the benefits of intraoperative mapping. Before this case series, the longest reported use of dexmedetomidine for awake craniotomy was 7 hours. 29 In our study, we found dexmedetomidine to be safe and well tolerated in a longer case (9 h) requiring multiple episodes of neurological testing during tumor resection. The choice of dexmedetomidine as the primary intraoperative agent for sedation and analgesia in this prolonged awake craniotomy is supported by its clinical application in intensive care. 18, 20, 30, 31 In our experience, the clinical sedative effect of dexmedetomidine may vary from person to person based on their body weight, metabolism, sensitivity to drugs, and/or their use of concomitant medications for underlying comorbidities (eg, patients on chronic benzodiazepine for anxiety disorders). However, the intraoperative synergistic interaction between dexmedetomidine with low doses of opioid and benzodiazepine (Table 5 ) and a careful titration of these drugs according to the different timings of the procedure allowed us to successfully perform awake craniotomy while ensuring the patient's cooperation, proper sedation, and airway and hemodynamic control. Similarly, we found dexmedetomidine to be very well tolerated in elderly patients with complex comorbidities.
In our experience, the initial effective bolus dose of dexmedetomidine is 0.5 to 1 mg/kg followed by a continuous infusion in the range of 0.3 to 0.7 mg/kg/h. The optimal time to stop the dexmedetomidine infusion is during dural opening. This timing allows the patients to reach a RASS of 0 before the neurological testing that often occurred 10 to 15 minutes following dural opening (Fig. 1) .
At the beginning of the procedure, scalp nerve blocks performed with 20 to 25 mL of bupivacaine 0.375%, and the infiltration of the incision line with 6 to 10 mL of bupivacaine 0.5% mostly controlled somatic pain secondary to the initial scalp incision and bone drilling. 32 However, these did little to control the visceral pain secondary to the dura incision and a rescue topical analgesic such as lidocaine 2% during dural manipulation might be used if patients experience breakthrough pain. In addition, low-dose boluses of midazolam are important to reduce patient anxiety during the initial and usually more stressful moments of the procedure. Similarly, opioids are beneficial to prevent and control episodes of breakthrough pain at the beginning and the end of the procedure without affecting patient cooperation or respiratory drive. In our experience, the use of remifentanil seems to be indicated only for prolonged procedures to ensure a constant synergistic interaction with dexmedetomidine (Fig. 2) .
The initial success with this technique applied in complex patients has encouraged us to consider its routine use for all awake craniotomy procedures at our institution. We are currently conducting studies to further define the safety and efficacy of dexmedetomidine in high-risk patients undergoing awake craniotomy and to assess the safety of this approach in comparison with the use of a remifentanilpropofol-based approach.
